Full-gene-sequencing analysis of N-acetyltransferase-2 in an adult Indian population

Genetic Testing and Molecular Biomarkers

Volumn 17, Issue 3, 2013, Pages 188-194

  Tilak, Ashwini V ^a   Iyer, Sandhya N ^a   Mukherjee, Manjari S ^a,b   Singhal, Rekha S ^a   Lele, Smita S ^a  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^b Cumballa Hill Hospital and Heart Institute   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; ISONIAZID;

ACETYLATOR PHENOTYPE; ALLELE; ARTICLE; CONTROLLED STUDY; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE SEQUENCE; GENOTYPE; HAPLOTYPE; HUMAN; INDIA; NORMAL HUMAN; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS;

ARYLAMINE N-ACETYLTRANSFERASE; GENETICS, POPULATION; GENOTYPE; HAPLOTYPES; HUMANS; INDIA; LINKAGE DISEQUILIBRIUM; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84874291671     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2012.0258     Document Type: Article

References (38)

1. Anitha A, Banerjee M (2003) Arylamine N-acetyltransferase2 polymorphism in the ethnic populations of South India. Int J Mol Med 11:125-131.
2. Arif E, Vibhuti A, Alam P, et al. (2007) Association of CYP2E1 and NAT2 gene polymorphisms with chronic obstructive pulmonary disease. Clinica Chimica Acta 382:37-42. (Pubitemid 46782729)
3. Bakayev V, Mohammadi F, Bahadori M, et al. (2004) Arylamine N-acetyltransferase 2 slow acetylator polymorphisms in unrelated Iranian individuals. Eur J Clin Pharmacol 60:467-471. (Pubitemid 39350159)
4. Batra J, Sharma SK, Ghosh B (2006) Arylamine N-acetyltransferase gene polymorphisms: markers for atopic asthma, serum IgE and blood eosinophil counts. Pharmacogenomics 7:673-682. (Pubitemid 44219398)
5. Blum M, Demierre A, Grant DM, et al. (1991) Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci U S A 88:5337-5241.
6. Blum M, Grant DM, McBride W, et al. (1990) Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol 9:193-203.
7. Butcher NJ, Boukouvala S, Sim E, et al. (2002) Pharmacogenetics of the arylamine N-acetyltransferase. Pharmacogenomics J 2:30-42.
8. Chen J, Stampfer MJ, Hough HL, et al. (1998) A prospective study of N-acetyltransferase genotype, red meat intake, and risk of colorectal cancer. Cancer Res 58:3307-3311. (Pubitemid 28371070)
9. Doll MA, Fretland FJ, Deitz AC, et al. (1995) Determination of human NAT2 acetylator genotype by restriction fragment length polymorphism and allele-specific amplification. Analyt Biochem 231:413-420.
10. Dupert JM, Grant DM (1992) Site-directed mutagenesis of recombinant arylamine N-acetyltransferase expressed in Escherichia coli. Evidence for direct involvement of Cys68 in the catalytic mechanism of polymorphic human NAT2. J Biol Chem 267:7381-7385.
11. Evans DA (1989) N-acetyltransferase. Pharmacol Ther 42:157- 234. (Pubitemid 19140452)
12. Gawronska-Szklarz B, Pawlik A, Czaja-Bulsa G, et al. (2001) Genotype of N-acetyltransferase 2 (NAT2) polymorphism in children with immunoglobulin E-mediated food allergy. Clin Pharmacol Ther 69:372-378. (Pubitemid 32477079)
13. Grant DM, Tang BK, Kalow WA (1984) A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol 17:43-50.
14. Hein DW, Grant DM, Sim E (2000) Update on consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogenetics 10:291-292. (Pubitemid 30345176)
15. Hein DW, Doll MA, Rustan TD, et al. (1993) Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 14:1633-1638. (Pubitemid 23249371)
16. Hickman D, Risch A, Buckle V, et al. (1994) Chromosomal localization of human genes for arylamine N-acetyltrasferase. Biochem J 297:441-445. (Pubitemid 24056093)
17. Hiratsuka M, Kishikawa Y, Takekuma Y, et al. (2002) Genotyping of the N-acetyltransferase2 polymorphism in the prediction of adverse drug reactions to isoniazid in Japanese patients. Drug Metab Pharmacokinet 17:357-362.
18. Hughes HB, Biehl JP, Jones AP, et al. (1954) Metabolism of isoniazid in man as related to occurrence of peripheral neuritis. Am Rev Res Dis 70:266-273.
19. Kukongviriyapan V, Prawan A, Tassaneyakul W, et al. (2003) Arylamine N-acetyltransferase-2 genotypes in the Thai population. Br J Clin Pharmacol 55:278-281. (Pubitemid 36390758)
20. Lee SY, Lee AK, Ki CS, et al. (2002) Complete sequencing of a genetic polymorphism in NAT2 in the Korean population. Clin Chem 48:775-777.
21. Loktionov A, Moore W, Spencer SP, et al. (2002) Differences in N-acetylation genotypes between Caucasians and black South Africans: implications for cancer prevention. Cancer Detect Prev 26:15-22. (Pubitemid 36087177)
22. Lower GM, Nilsson T, Nelson CE, et al. (1979) N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ Health Perspect 29:71-79. (Pubitemid 9190956)
23. Malik MA, Upadhyay R, Modi DR, et al. (2009) Association of NAT2 gene polymorphisms with susceptibility to esophageal and gastric cancers in the Kashmir valley. Arch Med Res 40:416-423.
24. Morton LM, Schenk M, Hein DW, et al. (2006) Genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2) and risk of nonhodgkin lymphoma. Pharmacogenet Genomics 16:537-545. (Pubitemid 44100198)
25. Nerbert DW, Ingelman-Sundberg M, Daly AK (1999) Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug metabolizing enzyme genes, their functional importance and nomenclature issues. Drug Metab Rev 31:467-487. (Pubitemid 29222673)
26. Pande JN, Singh SPN, Khilnani GC, et al. (1996) Risk factors for hepatotoxicity from anti-tuberculosis drugs: a case-control study. Thorax 50:132-136. (Pubitemid 26060649)
27. Pandey SN, Modi DR, Choudhuri G, et al. (2007) Slow acetylator genotype of N-acetyltransferase2 (NAT2) is associated with increased susceptibility to gallbladder cancer. Cancer biol therap 61:91-96. (Pubitemid 46294184)
28. Parkin DP, Vandenplas S, Botha FJ, et al. (1997) Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med 155:1712- 1722.
29. Patin E, Barreiro LB, Sabeti PC, et al. (2006a) Deciphering the ancient and complex evolutionary history of human arylamine N-acetyltransferase genes. Am J Hum Genet 78:423-436. (Pubitemid 43291225)
30. Patin E, Harmant C, Kidd KK, et al. (2006b) Sub-Saharan African coding sequence variation and haplotypes diversity at the NAT2 gene. Hum Mutat 27:720.
31. Singh N, Dubey S, Chinnaraj S, et al. (2009) Study of NAT2 gene polymorphisms in an Indian population. Mol Diag Therap 13:49-58.
32. Stephens M, Donnelly PA (2003) Comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73:1162-1169. (Pubitemid 37414228)
33. Stephens M, Scheet P (2005) Accounting for decay of linkage disequilibrium in haplotype inference and missing data imputation. Am J Hum Genet 76:449-462. (Pubitemid 40250525)
34. Stephens M, Smith NJ, Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978-989. (Pubitemid 32289743)
35. Vatsis KP, Martell KJ, Weber WW (1991) Diverse point mutations in the human gene for polymorphic N-acetyltransferase. Proc Natl Acad Sci U S A 88:6333-6337. (Pubitemid 21914940)
36. Weber WW, Hein DW (1985) N-Acetylation pharmacogenetics. Pharmacol Rev 37:25-79. (Pubitemid 15081093)
37. Zang Y, Zhao S, Doll MA, et al. (2004) The T341C (Ile114Thr) polymorphism of N-acetyltransferase 2 yields slow acetylator phenotype by enhanced protein degradation. Pharmacogenetics 14:717-723. (Pubitemid 39552786)
38. Zhu J, Chang P, Bondy ML, et al. (2003) Detection of 2-amino-1- methyl-6-phenylimidazo[4,5-b]-pyridine-DNA adducts in normal breast tissues and risk of breast cancer. Cancer Epidemiol Biomarkers Prev12:830-837.